Clinical Trials Logo

Pulmonary Carcinoid Tumor clinical trials

View clinical trials related to Pulmonary Carcinoid Tumor.

Filter by:
  • Withdrawn  
  • Page 1

NCT ID: NCT04915144 Withdrawn - Clinical trials for Neuroendocrine Tumors

177Lu-DOTATOC for the Treatment of Patients With Somatostatin Receptor Positive NETs

Start date: January 15, 2023
Phase: Phase 2
Study type: Interventional

This study is to assess if personalized peptide receptor radionuclide therapy (PRRT) with 177Lu-DOTATOC results in fewer adverse events than standard PRRT. Subjects will be randomized to either receive personalized or standard PRRT. Personalized PRRT will be determined based on dosimetry calculations after the first cycle. In addition comparisons, will be made with progression-free survival, serial CT imaging, ctDNA, and quality of life questionnaires. Subjects will be followed for 5 years or until they have progression and are switched to another systemic treatment (not including treatment with somatostatin analogues).